Events:
There were 17 events in the standard therapy group (15 relapses, and 2
treatment related death due to liver failure and sepsis), while patients
treated in the augmented therapy group had 6 events (one died of second
cancer/ AML, 2 relapsed, and 3 had refractory disease). The median time
to relapse for all patients was 13.8 months (range, 6-55 months). Eleven
of 17 patients who relapsed (65%) had isolated BM relapse, 4 had
isolated extramedullary relapse, and 2 had combined relapse (BM+CNS).
Six patients (35%) achieved CR2 after salvage chemotherapy, of them
three patients underwent allogenic -HCT in CR2, only one patient alive
in continuous complete remission (CCR) post-transplant; all others (N=5)
succumbed due to second relapses.